GIM
ALT icon

Glenmede Investment Management’s Altimmune ALT Stock Holding History

Glenmede Investment Management’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,465
Closed -$79.2K – 1435
2025
Q2 		$79.2K Buy
+20,465
New +$111K ﹤0.01% 1331

Other funds holding ALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Glenmede Investment Management's ALT Position: Q3 2025 in Review

Glenmede Investment Management sold out of Altimmune (ALT) in Q3 2025, closing a stake of 20,465 shares — an estimated $79.2K sold.

Glenmede Investment Management first reported a position in ALT in Q2 2025 and held it in 1 quarter. The position peaked at $79.2K in Q2 2025. 158 funds tracked by Wall St. Rank hold ALT as of Q3 2025.

  • Glenmede Investment Management reported no remaining Altimmune position as of Q3 2025 after selling out during the quarter.
  • Glenmede Investment Management sold 20,465 Altimmune shares in Q3 2025, an estimated $79.2K.
  • Glenmede Investment Management first reported a position in Altimmune in Q2 2025 and held it in 1 quarter.
  • Glenmede Investment Management's Altimmune position peaked at $79.2K in Q2 2025.
  • 158 funds tracked by Wall St. Rank held Altimmune as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.